田纳西州 的 结直肠癌 临床试验
田纳西州 有 76 项针对 结直肠癌 的研究正在招募参与者。
田纳西州 的城市
官方研究文本（英文）
A Phase 1 Study Evaluating DISP-10 in Participants With Advanced Gastrointestinal Cancers
- Tennessee Oncology, Nashville
招募中1 期
18 岁及以上 · 所有性别 · 更新于 2026年10月5日 · NCT07544589A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer
- Sarah Cannon Research Institute Oncology Partners, Nashville
招募中2 期
18 岁及以上 · 所有性别 · 更新于 2026年10月5日 · NCT07659795A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
- Tennessee Oncology, Nashville
招募中1 期
18 岁及以上 · 所有性别 · 更新于 2026年10月2日 · NCT06270706The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Sarah Cannon Research Institute, Nashville
招募中1/2 期
12 岁及以上 · 所有性别 · 更新于 2026年10月2日 · NCT04585750A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
- SCRI Oncology Partners, Nashville
招募中2 期
18 岁及以上 · 所有性别 · 更新于 2026年10月2日 · NCT06760819Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, ERASur Trial
- Baptist Memorial Hospital and Cancer Center-Memphis, Memphis
- Vanderbilt University/Ingram Cancer Center, Nashville
招募中2 期
18 岁及以上 · 所有性别 · 更新于 2026年10月2日 · NCT05673148Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
- Exelixis Clinical Site #3, Nashville
招募中1 期
18 岁及以上 · 所有性别 · 更新于 2026年10月1日 · NCT05176483Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
- SCRI Oncology Partners, Nashville
招募中1 期
18 岁及以上 · 所有性别 · 更新于 2026年10月1日 · NCT06625775Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
- Baptist Cancer Center - Memphis, Memphis
- SCRI Oncology Partners, Nashville
- Tennessee Oncology, Pllc, Nashville
招募中1/2 期
18 岁及以上 · 所有性别 · 更新于 2026年9月30日 · NCT06324357A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
- Research Site, Nashville
招募中1 期
18 岁及以上 · 所有性别 · 更新于 2026年9月29日 · NCT05877599Testing the Addition of an Anti-Cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment (Capecitabine) for Metastatic or Unresectable Cancers
- Vanderbilt Breast Center at One Hundred Oaks, Nashville
- Vanderbilt University/Ingram Cancer Center, Nashville
招募中1 期
18 岁及以上 · 所有性别 · 更新于 2026年9月29日 · NCT05803382Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
- Henry-Joyce Cancer Clinic, Nashville
招募中3 期
18 岁及以上 · 所有性别 · 更新于 2026年9月28日 · NCT07222800A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
- Tennessee Oncology Chattanooga, Chattanooga
- SCRI Oncology Partners, Nashville
- Tennessee Oncology, Nashville
- 以及另外 1 项
招募中3 期
18 岁及以上 · 所有性别 · 更新于 2026年9月25日 · NCT06750094A Study of GSK5764227 in Combination With Standard of Care (SoC) or Other Agents in Participants With Advanced Solid Tumors
- GSK Investigational Site, Nashville
招募中1 期
18 岁及以上 · 所有性别 · 更新于 2026年9月25日 · NCT07277270Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
- Vanderbilt University Medical Center, Nashville
招募中观察性研究
18 岁及以上 · 所有性别 · 更新于 2026年9月25日 · NCT04981119A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer
- Vanderbilt Ingram Cancer Center, Nashville
招募中1/2 期
18 岁及以上 · 所有性别 · 更新于 2026年9月25日 · NCT05379595Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
- Research Site, Nashville
招募中1 期
18 岁及以上 · 所有性别 · 更新于 2026年9月25日 · NCT06218914A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
- SCRI Oncology Partners, Nashville
招募中3 期
18 岁及以上 · 所有性别 · 更新于 2026年9月25日 · NCT06662786A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors
- SCRI Oncology Partners, Nashville
招募中1 期
18 岁及以上 · 所有性别 · 更新于 2026年9月25日 · NCT06004245Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
- Vanderbilt University Medical Center, Nashville
招募中1/2 期
18 岁及以上 · 所有性别 · 更新于 2026年9月24日 · NCT06047379Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial
- Vanderbilt University/Ingram Cancer Center, Nashville
招募中3 期
18 岁及以上 · 所有性别 · 更新于 2026年9月24日 · NCT05863195A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer
- Local Institution - 0333, Nashville
- SCRI Oncology Partners, Nashville
招募中2/3 期
18 岁及以上 · 所有性别 · 更新于 2026年9月23日 · NCT07221357Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
- Research Site, Nashville
招募中2 期
18 至 130 岁 · 所有性别 · 更新于 2026年9月23日 · NCT05489211Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
- SCRI Oncology Partners, Nashville
招募中1/2 期
18 岁及以上 · 所有性别 · 更新于 2026年9月22日 · NCT06445062Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
- Sarah Cannon Research Institue, Nashville
招募中1/2 期
18 岁及以上 · 所有性别 · 更新于 2026年9月22日 · NCT06128551A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
- Tennessee Oncology, PLLC, Nashville
招募中1/2 期
18 岁及以上 · 所有性别 · 更新于 2026年9月21日 · NCT07629960Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
- Sarah Canon Research Institute (SCRI) Oncology Partners, Nashville
招募中1/2 期
18 岁及以上 · 所有性别 · 更新于 2026年9月16日 · NCT05786924A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors
- GSK Investigational Site, Nashville
招募中1/2 期
18 岁及以上 · 所有性别 · 更新于 2026年9月16日 · NCT07213609A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer
- Provision Center For Biomedical Research, Knoxville
招募中3 期
18 岁及以上 · 所有性别 · 更新于 2026年9月15日 · NCT07284849A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)
- SCRI Oncology Partners, Nashville
招募中1 期
18 岁及以上 · 所有性别 · 更新于 2026年9月11日 · NCT04929223Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer
- Vanderbilt University/Ingram Cancer Center, Nashville
招募中1 期
18 岁及以上 · 所有性别 · 更新于 2026年9月9日 · NCT06696768A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors
- Sarah Cannon Research Center, Nashville
招募中1 期
18 岁及以上 · 所有性别 · 更新于 2026年9月9日 · NCT06440005A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)
- SCRI Oncology Partners, Nashville
招募中3 期
18 岁及以上 · 所有性别 · 更新于 2026年9月9日 · NCT07549412Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer
- Clinical Study Site, Germantown
- Clinical Study Site, Hermitage
招募中3 期
18 岁及以上 · 所有性别 · 更新于 2026年9月8日 · NCT07228832Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation
- Tennessee Oncology PLLC - Chattanooga, Nashville
- Tennessee Oncology, PLLC, Nashville
- Vanderbilt University Medical Center, Nashville
招募中3 期
18 岁及以上 · 所有性别 · 更新于 2026年9月3日 · NCT06252649A Randomized Phase 2 Trial of Fruquintinib and TAS-102 as Compared to Fruquintinib in Patients With Refractory Advanced/Metastatic Colorectal Cancer
- Vanderbilt University Medical Center, Nashville
招募中2 期
18 岁及以上 · 所有性别 · 更新于 2026年9月1日 · NCT06992258Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- Saint Jude Children's Research Hospital, Memphis
招募中1/2 期
12 Months – 30 Years · 所有性别 · 更新于 2026年8月25日 · NCT04851119MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
- Sarah Cannon Research Institute, Nashville
- USO - US Oncology Research Network, Nashville
- Vanderbilt University School of Medicine, Nashville
招募中1 期
18 岁及以上 · 所有性别 · 更新于 2026年8月24日 · NCT06586515A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer
- Research Site, Nashville
招募中2 期
18 至 130 岁 · 所有性别 · 更新于 2026年8月18日 · NCT06792695FOG-001 in Locally Advanced or Metastatic Solid Tumors
- Sarah Cannon Research Institute, Nashville
- Vanderbilt Ingram Cancer Center, Nashville
招募中1/2 期
18 岁及以上 · 所有性别 · 更新于 2026年8月17日 · NCT05919264数据来自 ClinicalTrials.gov，检索日期：2026年10月6日。每项研究自行设定入选标准，由研究团队决定谁能参与。